ksx01-tcrt cell therapy
Refractory Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical SciencesCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Refractory Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rapamycin Samsung Medical Center | Phase 4 | BB |
su011248 Samsung Medical Center | Phase 4 | BB |
Hydralazine National Institute of Cancerología | Phase 2 | B |
Valproic Acid National Institute of Cancerología | Phase 2 | B |
(+)-VINCRISTINE Theodore Laetsch | Phase 1/2 | CCC |
View all 36 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →